Condition:   Spinal Cord Injury
Interventions:   Device: ReJoyce Workstation;   Other: Standard Care
Sponsors:   University of Melbourne;   Victorian Neurotrauma Initiative;   Life Time Care and Support Authority (NSW);   University of Western Australia
Recruiting - verified March 2010

Condition:   Malignant Melanoma
Interventions:   Drug: ABI-007;   Drug: Dacarbazine
Sponsors:   Abraxis BioScience Inc.;   University of Arizona
Recruiting - verified August 2009

Condition:   Huntington's Disease
Interventions:   Drug: Creatine Monohydrate (HD-02);   Drug: placebo
Sponsors:   Massachusetts General Hospital;   University of Rochester;   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified December 2008

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate
Sponsors:   European Organization for Research and Treatment of Cancer;   Lymphoma Trials Office;   Groupe d'Etudes de Lymphomes de L'Adulte;   Grup per l'Estudi dels Limfomes de Catalunya i Balears;   NCIC Clinical Trials Group;   Australasian Leukaemia and Lymphoma Group (ALLG);   Nordic Lymphoma Group
Active, not recruiting - verified June 2009

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010